Neurocrine Biosciences, Inc.

DB:NB3 Stock Report

Market Cap: €13.1b

Neurocrine Biosciences Management

Management criteria checks 4/4

Neurocrine Biosciences' CEO is Kyle Gano, appointed in Jan 2011, has a tenure of 13.92 years. total yearly compensation is $5.99M, comprised of 10.1% salary and 89.9% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth €17.57M. The average tenure of the management team and the board of directors is 7 years and 9.2 years respectively.

Key information

Kyle Gano

Chief executive officer

US$6.0m

Total compensation

CEO salary percentage10.1%
CEO tenure13.9yrs
CEO ownership0.1%
Management average tenure7yrs
Board average tenure9.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kyle Gano's remuneration changed compared to Neurocrine Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$386m

Jun 30 2024n/an/a

US$339m

Mar 31 2024n/an/a

US$370m

Dec 31 2023US$6mUS$603k

US$250m

Sep 30 2023n/an/a

US$191m

Jun 30 2023n/an/a

US$176m

Mar 31 2023n/an/a

US$64m

Dec 31 2022US$5mUS$551k

US$155m

Sep 30 2022n/an/a

US$58m

Jun 30 2022n/an/a

US$12m

Mar 31 2022n/an/a

US$71m

Dec 31 2021US$6mUS$517k

US$90m

Sep 30 2021n/an/a

US$445m

Jun 30 2021n/an/a

US$365m

Mar 31 2021n/an/a

US$402m

Dec 31 2020US$7mUS$488k

US$407m

Sep 30 2020n/an/a

US$93m

Jun 30 2020n/an/a

US$205m

Mar 31 2020n/an/a

US$177m

Dec 31 2019US$5mUS$443k

US$37m

Sep 30 2019n/an/a

US$21m

Jun 30 2019n/an/a

US$18m

Mar 31 2019n/an/a

-US$39m

Dec 31 2018US$5mUS$403k

US$21m

Sep 30 2018n/an/a

US$10m

Jun 30 2018n/an/a

-US$52m

Mar 31 2018n/an/a

-US$106m

Dec 31 2017US$2mUS$375k

-US$143m

Compensation vs Market: Kyle's total compensation ($USD5.99M) is about average for companies of similar size in the German market ($USD4.86M).

Compensation vs Earnings: Kyle's compensation has been consistent with company performance over the past year.

CEO

Kyle Gano (51 yo)

13.9yrs

Tenure

US$5,990,215

Compensation

Mr. Kyle W. Gano, Ph D., is CEO and Director at Neurocrine Biosciences, Inc since October 11, 2024. He was Chief Business Development and Strategy Officer at Neurocrine Biosciences, Inc. since 2020 until O...

Leadership Team

NamePositionTenureCompensationOwnership
Kyle Gano
CEO & Director13.9yrsUS$5.99m0.13%
€ 17.6m
Matthew Abernethy
Chief Financial Officer7.1yrsUS$6.06m0.031%
€ 4.1m
Jude Onyia
Chief Scientific Officer3.1yrsUS$7.22m0.015%
€ 2.0m
Eiry Roberts
Chief Medical Officer6.9yrsUS$5.87m0.031%
€ 4.0m
Lawrence Steinman
Co-Founder of Neurocrineno datano datano data
Jane Sorensen
Head of Investor Relationsno datano datano data
Darin Lippoldt
Chief Legal Officer & Corporate Secretary10.2yrsUS$4.72m0.039%
€ 5.2m
Julie Cooke
Chief Human Resources Officer7.3yrsno data0.018%
€ 2.4m
Eric Benevich
Chief Commercial Officer9.6yrsUS$5.81m0.040%
€ 5.3m
David Boyer
Chief Corporate Affairs Officer5.3yrsno data0.00037%
€ 48.6k
Ingrid Delaet
Chief Regulatory Officer2.2yrsno data0.0025%
€ 325.9k
Christopher O'Brien
Exclusive Consultant6.9yrsUS$3.10mno data

7.0yrs

Average Tenure

58yo

Average Age

Experienced Management: NB3's management team is seasoned and experienced (7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kyle Gano
CEO & Directorless than a yearUS$5.99m0.13%
€ 17.6m
Christine Poon
Independent Director1.4yrsUS$813.45k0%
€ 0
Richard Pops
Independent Director26.7yrsUS$492.04k0.031%
€ 4.1m
Stephen Sherwin
Independent Director25.7yrsUS$479.54k0.024%
€ 3.2m
William Rastetter
Independent Chairman of the Board14.8yrsUS$495.04k0.037%
€ 4.9m
Gary Lyons
Independent Director31.8yrsUS$460.11k0.12%
€ 15.5m
George Morrow
Independent Director9.2yrsUS$479.54k0.0042%
€ 545.3k
Kevin Gorman
Director16.9yrsUS$15.75m0.51%
€ 66.8m
Shalini Sharp
Independent Director4.8yrsUS$497.11k0.00098%
€ 128.8k
Leslie Norwalk
Independent Director5.3yrsUS$475.11k0.00098%
€ 128.8k
Johanna Mercier
Independent Director3.7yrsUS$467.61k0.0021%
€ 272.0k

9.2yrs

Average Tenure

66yo

Average Age

Experienced Board: NB3's board of directors are considered experienced (9.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:28
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Neurocrine Biosciences, Inc. is covered by 50 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Martha FreitagArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research